Study of Heart and Renal Protection Extended Review (SHARP-ER)

Patients with chronic kidney disease (CKD) have significant increases in cardiovascular morbidity and mortality, hospitalisation rates and reduced quality of life, with few treatments proven to reduce this increasing burden of disease.

The main findings of the SHARP study showed that a treatment combination of two drugs, simvastatin and ezetimibe to lower blood cholesterol levels, reduced the risk of heart attacks, strokes, and operations to open blocked arteries in people with chronic kidney disease, by about 17%.

The follow-up Study, SHARP Extended Review (‘SHARP-ER’) followed a group of the patients who took part in the original SHARP study (from Australia, New Zealand and Malaysia) for a further five years. This data will be used to find out whether the beneficial effects of cholesterol-lowering treatment seen in the original SHARP study persist in the longer term and to understand the economic and social impact of CKD on patients and their families.


Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort.

Sukkar L, Talbot B, Jun M, Dempsey E, Walker R, Hooi L, Cass A, Jardine M, Gallagher M. Canadian Journal of Kidney Health and Disease. 2019 Oct 14;6:2054358119879896. doi: 10.1177/2054358119879896. eCollection 2019.